Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries. The four studies have achieved the Company's enrollment targets, with a total of approximately 35 adult and adolescent patients with aHUS.

“Given the potential for rapid and life-threatening deterioration observed in patients with aHUS, and the inability to predict sudden worsening in an individual, we are increasingly focused on diligently advancing our development efforts. We look forward to presenting preliminary results from these studies later in 2010”


Alexion Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
A simple method to prepare carbon isotope-labeled versions of drugs and diagnostics